Frontier Airlines Again Proposes Merger With Rival Carrier Spirit
U.S. discount carrier Frontier Airlines (ULCC) is again proposing to merge with its rival Spirit Airlines (SAVE), which is currently involved in bankruptcy proceedings.Frontier and Spirit first announced a merger back in 2022, but another takeover bid from JetBlue Airways (JBLU) ended up scuttling that deal. Then, JetBlue’s acquisition of Spirit Airlines was blocked by a federal judge, citing competition concerns in the domestic U.S. aviation industry.Left on its own, Spirit Airlines, which has struggled financially since the Covid-19 pandemic in 2020, filed for Chapter 11 bankruptcy last November.The original merger offer from Frontier Airlines had valued Spirit at $2.9 billion U.S. It’s not clear what the value would be now that Spirit has entered bankruptcy. Frontier said in a news release that it has met with Spirit’s board of directors and senior executives before announcing the renewed merger proposal. The statement from Frontier also says that Spirit’s plans to emerge from bankruptcy as a standalone company will “likely result in an unprofitable airline with a high debt load and limited likelihood of success.”The new merger proposal comes as corporate America bets on a more friendly view of industry consolidations and takeovers under the new administration of U.S. President Donald Trump. Frontier Airlines’ stock has gained 42% over the past year to trade at $7.78 U.S. a share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


